CN113278596B - 可提高芽孢杆菌核苷产量的突变体及其应用 - Google Patents

可提高芽孢杆菌核苷产量的突变体及其应用 Download PDF

Info

Publication number
CN113278596B
CN113278596B CN202110567676.9A CN202110567676A CN113278596B CN 113278596 B CN113278596 B CN 113278596B CN 202110567676 A CN202110567676 A CN 202110567676A CN 113278596 B CN113278596 B CN 113278596B
Authority
CN
China
Prior art keywords
gly
ala
glu
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110567676.9A
Other languages
English (en)
Other versions
CN113278596A (zh
Inventor
孙莹莹
胡丹
齐丹丹
吴涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Langfang Meihua Bio Technology Development Co Ltd
Original Assignee
Langfang Meihua Bio Technology Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Langfang Meihua Bio Technology Development Co Ltd filed Critical Langfang Meihua Bio Technology Development Co Ltd
Priority to CN202110567676.9A priority Critical patent/CN113278596B/zh
Publication of CN113278596A publication Critical patent/CN113278596A/zh
Application granted granted Critical
Publication of CN113278596B publication Critical patent/CN113278596B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1077Pentosyltransferases (2.4.2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/38Nucleosides
    • C12P19/40Nucleosides having a condensed ring system containing a six-membered ring having two nitrogen atoms in the same ring, e.g. purine nucleosides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/02Pentosyltransferases (2.4.2)
    • C12Y204/02014Amidophosphoribosyltransferase (2.4.2.14)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/05Carbon-nitrogen ligases with glutamine as amido-N-donor (6.3.5)
    • C12Y603/05003Phosphoribosylformylglycinamidine synthase (6.3.5.3)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明涉及生物工程领域,具体涉及可提高芽孢杆菌核苷产量的突变体及其应用。所述突变体包括:1)磷酸核糖基甲酰基甘氨酰胺合酶突变体,其在序列如SEQ ID NO.2或SEQ ID NO.6所示的磷酸核糖基甲酰基甘氨酰胺合酶的基础上,第444位丝氨酸突变为苯丙氨酸;和/或,2)酰胺基磷酸核糖基转移酶突变体,其在序列如SEQ ID NO.4或SEQ ID NO.8所示的酰胺基磷酸核糖基转移酶的基础上,第312位亮氨酸突变为脯氨酸。本发明的突变体均仅需突变一个氨基酸位点即可在芽孢杆菌获得更高的核苷产量,可有效积累肌苷、腺苷、鸟苷等核苷,实用性更广,有利于降低核苷工业化生产的成本。

Description

可提高芽孢杆菌核苷产量的突变体及其应用
技术领域
本发明涉及生物工程领域,具体涉及可提高芽孢杆菌核苷产量的突变体及其应用。
背景技术
基因工程菌以细菌作为宿主菌优势明显,如发酵周期短、原料要求简单、基因工程技术成熟等。目前,微生物发酵是生产核苷主要的方法,所用生产菌主要是芽孢杆菌类,包括解淀粉芽孢杆菌、枯草芽孢杆菌及短小芽孢杆菌等。芽孢杆菌类作为核苷的出发菌株,其优势是磷酸戊糖途径比较活跃,嘌呤核苷磷酸化酶活力低。在芽孢杆菌属中,包括枯草芽孢杆菌在内的许多菌株具有可靠的安全性。传统菌株选育发现,芽孢杆菌的突变株能够过量合成叶酸、腺苷、肌苷、鸟苷、核黄素等一系列嘌呤途径代谢中间产物或该途径的衍生代谢产物,成为选育高产核苷类代谢产物重要出发菌株。但目前生产上大多为芽孢诱变菌种,遗传背景不清晰,成本高、转化率低,造成工业化生产水平普遍偏低。因此,亟待通过代谢工程的手段,改善菌种性能。
核苷是一类糖苷的总称。核苷是核酸和核苷酸的组成成分。核苷都是由D-核糖或D-Z-脱氧核糖与嘧啶碱或嘌呤碱缩合而成。由D-核糖生成的核苷称核糖核苷,参与RNA组成,由D-α-脱氧核糖生成的核苷称脱氧核糖核苷,参与DNA组成。腺苷即腺嘌呤核苷,化学名为6-氨基-9-β-D-呋喃核糖基-9-氢嘌呤,它是腺嘌呤核苷酸脱磷酸后的产物,属于重要的核苷酸衍生物。腺苷是一种遍布人体细胞的内源性核苷,可直接进入心肌经磷酸化生成腺苷酸,参与心肌能量代谢,同时还参与扩张冠脉血管,增加血流量,广泛应用于医药等行业。鸟苷,化学名称:9-β-D-呋喃核糖鸟嘌呤。可作为食品或医药原料的中间体,用于生产5’-鸟苷酸二钠、鸟嘌呤、利巴韦林、阿昔洛韦、泛昔洛韦等食品添加剂或医药原料。肌苷,化学名称:9-β-D-核糖次黄嘌呤。系细胞代谢改善药,参与体内核酸代谢,在体内转变为肌苷酸及三磷酸腺苷,参与细胞的能量代谢和蛋白质合成,提高各种酶,特别是辅酶A与丙酮酸氧化酶的活性,从而使细胞在缺氧状态下继续进行代谢,活化肝脏功能,促进受损伤肝脏的恢复,可刺激体内产生抗体并促进肠道对铁的吸收。
在微生物体内,核苷的生物合成途径有两条:分别是从头合成途径和补救合成途径。在工业微生物生产中,通过添加碳源、氮源、无机盐和生长因子为原材料,经过一系列酶促反应,从头合成生成核苷。在芽孢杆菌中,生产核苷需要经过一个包含12个基因的操纵子purEKBCSQLFMNHD(SEQ ID NO.25),称为嘌呤操纵子。嘌呤核苷酸生物合成的调控机制非常复杂,包括转录阻遏、转录衰减及末端产物反馈抑制等。而嘌呤操纵子的调控直接导致嘌呤核苷的产量。磷酸核糖基甲酰基甘氨酰胺合酶(由purL基因编码)和酰胺基磷酸核糖基转移酶(由purF基因编码)均是嘌呤从头合成途径的关键调节酶,酶活的高低直接影响进入嘌呤合成途径的通量。酰胺基磷酸核糖基转移酶受到ATP,AMP,GTP和GMP的反馈抑制作用。解除嘌呤途径受到的反馈抑制对于提高嘌呤途径的通量以及核苷类代谢产物的积累具有重要的意义。
枯草芽孢杆菌的嘌呤合成途径包括10步反应,其中催化这10步反应所需要的酶由嘌呤操纵子(pur operon)负责编码。嘌呤核苷酸生物合成的第一步是由磷酸戊糖焦磷酸激酶催化,核糖-5-磷酸同ATP反应生成5'-磷酸核糖焦磷酸(PRPP),随后经过9步反应生成肌苷酸(IMP),反应生成的IMP并不堆积在细胞内,而是迅速转变为腺苷酸(AMP)和鸟苷酸(GMP)。嘌呤从头合成是合成嘌呤核苷酸的主要途径,此过程要消耗氨基酸及ATP,同时嘌呤从头合成途径受到严格的多重调控机制。
虽然如CN1270631A中提到了通过发酵生产嘌呤核苷的方法,但其仅涉及大肠杆菌中的purF位点。CN103952422A提到了枯草芽孢杆菌编码PRPP转酰胺酶突变基因purF及应用,但其引入了2-3个氨基酸位点突变才仅仅最高使核黄素产量提高了20%,工作量较大且效果不显著。CN104232674A中提到了一种提高解淀粉芽孢杆菌生产鸟苷产量的方法,其在解淀粉芽孢杆菌中引入L217I位点,但仅使鸟苷产量提高了18%。
发明内容
本发明在大量研究中意外发现,将磷酸核糖基甲酰基甘氨酰胺合酶的第444位丝氨酸突变为苯丙氨酸,和/或,将酰胺基磷酸核糖基转移酶的第312位亮氨酸突变为脯氨酸时,可以更好地提升芽孢杆菌的核苷产量,且在两个酶同时上述突变时,对核苷产量的提升效果更优。基于上述发现,本发明提供了可提高芽孢杆菌核苷产量的突变体及其应用。
具体而言,第一方面,本发明首先提供可提高芽孢杆菌核苷产量的突变体,其包括:
1)磷酸核糖基甲酰基甘氨酰胺合酶突变体,其在序列如SEQ ID NO.2或SEQ IDNO.6所示的磷酸核糖基甲酰基甘氨酰胺合酶的基础上,第444位丝氨酸突变为苯丙氨酸;和/或,
2)酰胺基磷酸核糖基转移酶突变体,其在序列如SEQ ID NO.4或SEQ ID NO.8所示的酰胺基磷酸核糖基转移酶的基础上,第312位亮氨酸突变为脯氨酸。
作为优选,所述磷酸核糖基甲酰基甘氨酰胺合酶突变体源自解淀粉芽孢杆菌或枯草芽孢杆菌;优选编码编码磷酸核糖基甲酰基甘氨酰胺合酶野生型的基因的核苷酸系列如SEQ ID NO.1或SEQ ID NO.5所示。
作为优选,所述酰胺基磷酸核糖基转移酶突变体源自解淀粉芽孢杆菌或枯草芽孢杆菌;优选编码酰胺基磷酸核糖基转移酶野生型的基因的核苷酸系列如SEQ ID NO.3或SEQID NO.7所示。
第二方面,本发明还提供了编码所述突变体的核酸。
第三方面,本发明还提供了所述的突变体或核酸在以下任一方面的应用:
(1)构建高产核苷的芽孢杆菌;
(2)筛选高产核苷的芽孢杆菌;
优选地,所述芽孢杆菌为解淀粉芽孢杆菌或枯草芽孢杆菌。
进一步地,本发明还提供一种芽孢杆菌,其表达所述的突变体;和/或,其含有所述的核酸。
具体而言,其在下述至少一个位点发生了点突变:
1)氨基酸序列如SEQ ID NO.2或SEQ ID NO.6所示的磷酸核糖基甲酰基甘氨酰胺合酶的第444位丝氨酸突变为苯丙氨酸;
2)氨基酸序列如SEQ ID NO.4或SEQ ID NO.8所示的酰胺基磷酸核糖基转移酶的第312位亮氨酸突变为脯氨酸。
发明人发现,经上述突变的酶对芽孢杆菌积累核苷物质具有正效果。
purL是磷酸核糖基甲酰基甘氨酰胺合酶基因,是核苷合成的关键基因,是嘌呤合成途径中pur operon基因簇的重要组成部分之一,所以purL基因增强有利于嘌呤核苷合成。
之前有文献报道过可增加其拷贝数及改变调控区等方式强化pur operon,但没有通过点突变方式对该基因进行修饰。本发明则是通过purLS444F突变达到purL基因强化目的。
purF编码酰胺基磷酸核糖基转移酶,是嘌呤从头合成途径的关键调节酶,该酶活的高低直接影响进入嘌呤合成途径的通量。胺基磷酸核糖基转移酶受到ATP,AMP,GTP和GMP的反馈抑制作用。解除嘌呤途径受到的反馈抑制对于提高嘌呤途径的通量以及核苷类代谢产物或源于嘌呤途径代谢物的积累具有重要的意义。本发明则是通过purFL312P突变解除胺基磷酸核糖基转移酶的反馈抑制,进而增强酶活。
优选地,编码磷酸核糖基甲酰基甘氨酰胺合酶野生型的基因的核苷酸系列如SEQID NO.1或SEQ ID NO.5所示。
优选地,编码酰胺基磷酸核糖基转移酶野生型的基因的核苷酸系列如SEQ IDNO.3或SEQ ID NO.7所示。
作为优选,所述芽孢杆菌中同时发生了两个所述的点突变。
作为优选,所述芽孢杆菌为解淀粉芽孢杆菌或枯草芽孢杆菌。
在一些实施方案中,purLS444F、purFL312P单一位点突变分别获得解淀粉芽孢杆菌B.amyloliquefaciens G1、B.amyloliquefaciens G2菌株。两个单一点突变质粒依次转化B.amyloliquefaciens(Δupp)菌株获得两个位点均发生点突变的解淀粉芽孢杆菌B.amyloliquefaciens G3。实验显示,同出发菌株B.amyloliquefaciens13952Δupp相比,工程菌的核苷积累量都有提高,G1积累较少,G2积累较多,两个位点均发生点突变的G3菌株核苷积累最多,说明这两个位点的突变在核苷积累中起到了主要作用。
在一些实施方案中,purLS444F、purFL312P单一位点突变分别获得枯草芽孢杆菌B.subtilis E1、B.subtilis E2菌株。两个单一点突变质粒依次转化B.subtilis168(Δupp)菌株获得两个位点均发生点突变的枯草芽孢杆菌B.subtilis E3。实验显示,同出发菌株B.subtilis168Δupp相比,工程菌的核苷积累量都有提高,E1积累较少,E2积累较多,两个位点均发生点突变的E3菌株核苷积累最多,说明这两个位点的突变在核苷积累中起到了主要作用。
本发明还提供了上述芽孢杆菌的构建方法,包括:
步骤A、分别制备purLS444F、purFL312P点突变基因片段,与载体连接分别获得单一位点突变质粒;
步骤B、两个单一点突变质粒转化B.amyloliquefaciens 13952(Δupp)、B.subtilis168(Δupp)菌株获得单一位点突变的菌株。
在一些实施方案中,所述的构建方法中步骤A所述载体为pKSU。
在一些实施方案中,所述两个单一位点突变质粒分别为pKSU-purL*,pKSU-purF*,单一位点突变的解淀粉芽孢杆菌为B.amyloliquefaciensG1、B.amyloliquefaciens G2菌株;单一位点突变的枯草芽孢杆菌为B.subtilis E1、B.subtilis E2菌株。
在一些实施方案中,所述菌株的构建方法步骤B为两个单一点突变质粒依次转化B.amyloliquefaciens 13952(Δupp)、B.subtilis168(Δupp)菌株获得两个位点均发生点突变的解淀粉芽孢杆菌B.amyloliquefaciens G3和枯草芽孢杆菌B.subtilis E3。
第二方面,本发明还提供所述的芽孢杆菌在生产核苷中的应用。
作为优选,所述的核苷包括但不限于肌苷和腺苷。
进一步的,本发明还提供一种生产核苷的方法,包括:培养所述的芽孢杆菌,以产生、积累和收集核苷。
作为优选,所述方法包括:将所述芽孢杆菌接种于种子培养基进行扩繁,然后将扩繁后的培养物转入发酵培养基发酵。
作为优选,所述种子培养基中含有如下组分:
葡萄糖20g/L,酵母粉5g/L,玉米浆干粉5g/L,磷酸二氢钾3g/L,硫酸镁0.5g/L,硫酸亚铁0.02g/L,硫酸锰0.01g/L,pH 7.0~7.2。
作为优选,所述发酵培养基中含有如下组分:
葡萄糖60g/L,酵母粉3.5g/L,磷酸二氢钾3g/L,硫酸铵25g/L,硫酸锰0.01g/L,硫酸镁5g/L,味精10g/L,玉米浆干粉15g/L,碳酸钙25g/L,pH 7.0~7.2。
作为优选,所述发酵的温度为35-36℃,更优选为35.5℃。
在一些实施方案中,发酵时间为40-50h。
基于上述技术方案,本发明的有益效果如下:
本发明中的突变体均仅需突变一个氨基酸位点即可在芽孢杆菌中获得更高的核苷产量,可有效积累肌苷、腺苷、鸟苷及其它核苷类相关产品,实用性更广,有利于降低核苷工业化生产的成本。
附图说明
图1为解淀粉芽孢杆菌菌株产苷水平比较。
图2为枯草芽孢杆菌菌株产苷水平比较。
图3为工程菌株B.subtilis-E3-1、E3-2、E3-3和B.subtilis A5腺苷合成能力对比。
具体实施方式
以下实施例用于说明本发明,但不用来限制本发明的范围。
本发明所用到的原始菌株B.amyloliquefaciens 13952、B.subtilis 168为实验室保存,其可通过市售途径获得;B.subtilis A5已在CN110257315B中得到公开。本发明所用到的腺苷和肌苷标准品从Sigma公司(http://www.sigmaaldrich.com/sigma-aldrich)购买,所用DNA聚合酶、DNA纯化试剂盒、限制性内切酶、去磷酸化酶、DNA连接酶等分子生物学试剂从Thermo公司购买(http://www.thermoscientificbio.com/fermentas),所用其他生化试剂从生工生物工程(上海)股份有限公司购买(http://www.sangon.com/)。
其中,各实施例涉及的引物序列如表1(由上至下依次为SEQ ID NO.9-24)所示。
表1引物序列
引物 序列5'→3'
purL-A-1f caaaataaggatcctctagagtcgacgaagtcatccagtgcgacgc
purL-A-1r tctgagcactcccgcgtcaaagcccggagccaccaccgtg
purL-A-2f cacggtggtggctccgggctttgacgcgggagtgctcaga
purL-A-2r ccagtgccaagcttgcatgcctgcaggcgtcgcactggatgacttc
purF-A-1f caaaataaggatcctctagagtcgaccacttttcactgaaggatca
purF-A-1r aacggtttttaatgagaccgggttcgtacggaatgcccgt
purF-A-2f acgggcattccgtacgaacccggtctcattaaaaaccgtt
purF-A-2r ccagtgccaagcttgcatgcctgcaggcactgcttcttttacgtga
purL-S-1f caaaataaggatcctctagagtcgaccggtttaacaagctcaagtg
purL-S-1r tctgagaacaccagcatcaaacccaggagcgacaactgta
purL-S-2f tacagttgtcgctcctgggtttgatgctggtgttctcaga
purL-S-2r ccagtgccaagcttgcatgcctgcaggctttgccgtaaatacggcc
purF-S-1f caaaataaggatcctctagagtcgacaagaagcggacacttcacgc
purF-S-1r cggtttttgattaagccaggctcatacggaatgcctgttg
purF-S-2f caacaggcattccgtatgagcctggcttaatcaaaaaccg
purF-S-2r ccagtgccaagcttgcatgcctgcagatactgcttcttttacgtga
实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件,或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可通过正规渠道商购买得到的常规产品。
实施例1:工程菌株B.amyloliquefaciens G1(purLS444F),G2(purFL312P)的构建
用引物purL-A-1f/1r和purL-A-2f/2r和purF-A-1f/1r和purF-A-2f/2r,以B.amyloliquefaciens 13952基因组为模板,使用pfu高保真DNA聚合酶扩增分别得到purL和purF的上下游同源臂;用引物purL-A-1f/2r和purF-A-1f/2r融合上下游片段分别得到purL*同源片段(含S444F突变,完整purL*基因的核苷酸序列如SEQ ID No.1所示共2229bp,氨基酸序列如SEQ ID No.2所示共742个氨基酸序列)和purF*同源片段(含L312P突变,完整purF*基因的核苷酸序列如SEQ ID No.3所示共1431bp,氨基酸序列如SEQ ID No.4所示共476个氨基酸序列),将2个片段与pKSU(工具载体)质粒经SalI/PstI双酶切、连接、转化等操作后得到质粒pKSU-purL*和pKSU-purF*。通过电化学转化至B.amyloliquefaciens 13952中,用含2.5μg/mL氯霉素的LB平板在30℃下筛选转化子,将获得的转化子接到5ml LB液体中,42℃、200rpm培养12h并传一代,稀释涂布含5μg/mL的氯霉素LB平板获得一次重组子;将一次重组子接到5ml LB液体中,42℃、200rpm培养12h并传一代,稀释涂布含0.8μM 5-FU的LB平板筛选二次重组子,得到在B.amyloliquefaciens 13952(Δupp)引入purLS444F的B.amyloliquefaciens G1菌株,引入purFL312P的B.amyloliquefaciens G2菌株。
实施例2:工程菌株B.amyloliquefaciens G3构建(引入purLS444F&purFL312P突变)
将质粒pKSU-purL*转化至B.amyloliquefaciens G2菌株中,获得工程菌B.amyloliquefaciens G3(purLS444F&purFL312P突变),筛选方法同实施例1。
LB液体培养基配方为:10g/L蛋白胨,5g/L酵母提取物,10g/L NaCl,调节pH至7.2,0.15Mpa压力下灭菌20min。LB固体培养基配方为:在LB液体培养基中加入琼脂粉(终浓度18g/L),121℃下灭菌20min。
实施例3:工程菌株B.subtilisE1(purLS444F),E2(purFL312P)的构建
用引物purL-S-1f/1r和purL-S-2f/2r和purF-S-1f/1r和purF-S-2f/2r,以B.subtilis 168基因组为模板,使用pfu高保真DNA聚合酶扩增分别得到purL和purF的上下游同源臂;用引物purL-S-1f/2r和purF-S-1f/2r融合上下游片段分别得到purL*同源片段(含S444F突变,完整purL*基因的核苷酸序列如SEQ ID No.5所示共2229bp,氨基酸序列如SEQ ID No.6所示共742个氨基酸序列)和purF*同源片段(含L312P突变,完整purF*基因的核苷酸序列如SEQ ID No.7所示共1431bp,氨基酸序列如SEQ ID No.8所示共476个氨基酸序列),将2个片段与pKSU(工具载体)质粒经SalI/PstI双酶切、连接、转化等操作后得到质粒pKSU-purL*和pKSU-purF*。通过电化学转化至B.subtilis168中,用含2.5μg/mL氯霉素的LB平板在30℃下筛选转化子,将获得的转化子接到5ml LB液体中,42℃、200rpm培养12h并传一代,稀释涂布含5μg/mL的氯霉素LB平板获得一次重组子;将一次重组子接到5ml LB液体中,42℃、200rpm培养12h并传一代,稀释涂布含0.8μM 5-FU的LB平板筛选二次重组子,得到在B.subtilis168(Δupp)引入purLS444F的B.subtilis E1菌株,引入purFL312P的B.subtilis E2菌株。
实施例4:工程菌株B.subtilis E3构建(引入purLS444F&purFL312P突变)
将质粒pKSU-purL*转化至B.subtilis E2菌株中,获得工程菌B.subtilis E3(purLS444F&purFL312P突变),筛选方法同实施例3。
LB液体培养基配方为:10g/L蛋白胨,5g/L酵母提取物,10g/L NaCl,调节pH至7.2,0.15Mpa压力下灭菌20min。LB固体培养基配方为:在LB液体培养基中加入琼脂粉(终浓度18g/L),121℃下灭菌20min。
实施例5:工程菌株B.amyloliquefaciens G1、G2、G3和B.amyloliquefaciens13952以及B.subtilis-E1、E2、E3和B.subtilis 168肌苷合成能力对比
1.培养基:
(1)种子培养基配方(g/L):葡萄糖20,酵母粉5,玉米浆干粉5,磷酸二氢钾3,硫酸镁0.5,硫酸亚铁0.02,硫酸锰0.01,pH 7.0~7.2,121℃下灭菌20min。
(2)发酵培养基配方(g/L):葡萄糖60,酵母粉3.5,磷酸二氢钾3,硫酸铵25,硫酸锰0.01,硫酸镁5,味精10,玉米浆干粉15,碳酸钙25,pH 7.0~7.2,121℃下灭菌20min。
2.培养方法
(1)将菌株三区划线LB平板,37℃过夜培养;
(2)挑单菌落接种至30mL种子培养基中,110rpm,36℃培养7~8h;
(3)按10%接种量转接至30ml发酵培养基中,摇床转速130rpm,35.5℃培养46h;
发酵结果见图1,从结果可以看出,同出发菌株B.amyloliquefaciens13952相比,工程菌的核苷积累量都有提高,G1(purLS444F)和G2(purFL312P)单点工程菌肌苷积累量分别提高0.36g/L和0.45g/L,说明purLS444F的引入能够提高磷酸核糖基甲酰基甘氨酰胺合酶活性,purFL312P突变解除了PRPP转氨酶的反馈抑制。双突变工程菌G3(purLS444F&purFL312P)肌苷提高积累量1.13g/L,说明解淀粉芽孢杆菌这两个位点的突变在核苷积累中起到了主要作用。
发酵结果见图2,从结果可以看出,同出发菌株B.subtilis168相比,工程菌的核苷积累量都有提高,E1(purLS444F)和E2(purFL312P)单点工程菌肌苷积累量分别提高26.4mg/L和32.0mg/L,双突变工程菌E3(purLS444F&purFL312P)肌苷积累量提高102.3mg/L,说明枯草芽孢杆菌这两个位点的突变在核苷积累中起到了主要作用。
实施例6:工程菌株B.subtilis E3-1、E3-2、E3-3构建(引入purLS444F&purFL312P突变)
将质粒pKSU-purL*和pKSU-purF*转化至B.subtilis A5(CN110257315B)菌株中,获得工程菌B.subtilis E3-1和E3-2(purLS444F&purFL312P突变)。将质粒pKSU-purL*转化至B.subtilis E3-2菌株中,获得工程菌B.subtilis E3-3(purLS444F&purFL312P突变),以上筛选方法同实施例3。
实施例7:工程菌株B.subtilis-E3-1、E3-2、E3-3和B.subtilis A5腺苷合成能力对比
培养基及发酵方法同实施例5,发酵结果见图3,从结果可以看出,同出发菌株B.subtilis A5相比,工程菌的核苷积累量都有提高,E3-1(purLS444F)和E3-2(purFL312P)单点工程菌腺苷积累量分别提高1.2g/L和1.5g/L,双突变工程菌E3-3(purLS444F&purFL312P)腺苷积累量提高2.8g/L,说明枯草芽孢杆菌这两个位点的突变在核苷积累中起到了主要作用。
本发明的菌株的构建,其步骤的前后顺序不限定,本领域的技术人员按本发明公开的内容达到本发明的目的均属于本发明的保护范围。
本发明中的菌株代号如B.subtilis E1和B.subtilis E2等是为了方便描述,但不应理解为对本发明的限定。上述方法构建的包含磷酸核糖基甲酰基甘氨酰胺合酶基因purLS444F和PRPP转酰胺酶基因purFL312P的工程菌的用途,包括但是不局限于生产核苷。
虽然,上文中已经用一般性说明及具体实施方案对本发明作了详尽的描述,但在本发明基础上,可以对之作一些修改或改进,这对本领域技术人员而言是显而易见的。因此,在不偏离本发明精神的基础上所做的这些修改或改进,均属于本发明要求保护的范围。
序列表
<110> 廊坊梅花生物技术开发有限公司
<120> 可提高芽孢杆菌核苷产量的突变体及其应用
<130> KHP211111917.4
<160> 25
<170> SIPOSequenceListing 1.0
<210> 1
<211> 2229
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
atgtcgctac tgcttgaacc aagtaaagaa caaataaaag aagagaaact ctatcagcaa 60
atgggtgtca gtgatgacga gttcgcactc attgaatcta ttatcggaag attgccaaac 120
tacacggaaa tcgggatttt ttccgtgatg tggtcagagc actgcagcta taaaaattct 180
aagccgattt tacgcaaatt cccgacaagc ggcgaacgcg tgctgcaagg tcccggggaa 240
ggcgcgggga tcgttgacat cggtgacaat caggcggttg tgttcaaaat tgaatcgcat 300
aaccacccgt cagcgcttga gccataccag ggtgctgcga cgggagtggg cggcatcatc 360
cgtgacgttt tctcaatggg cgcccgtccg atagctgtat taaactctct tcgatttggt 420
gaactcactt caccgcgtgt gaagtacttg tttgaagaag tagtggctgg aatcgcggga 480
tacggaaact gtatcggcat tccgacggtc ggcggggaag ttcagtttga cgcaagctat 540
gagggcaatc cgcttgtcaa tgccatgtgc gtcggcctaa ttgatcataa ggatattaaa 600
aaaggccagg cgaaaggtgt cggcaacacg gttatgtacg tcggcgctaa gacgggacgc 660
gacggcattc acggcgctac tttcgcatca gaagaaatgt cagattcatc tgaagaaaaa 720
cgctccgcgg tgcaggtcgg cgatcctttc atggaaaagc ttcttcttga agcctgcctg 780
gaagtcatcc agtgcgacgc gttagtcggc attcaggata tgggagcggc cggtctgaca 840
agttcaagcg ctgaaatggc aagtaaagcc ggatcaggca ttgaaatgaa ccttgatctc 900
attccgcagc gggaaacggg tatgaccgct tatgaaatga tgctttccga atctcaggaa 960
cgcatgcttc tcgttattga acgcgggcgt gaacaggaaa ttgtcgatat ttttaataaa 1020
tatgatcttg aagcggtttc cgtgggtcat gtcacggatg ataaaatgct ccgcctccgc 1080
cataacggag aggttgtttg cgagcttccg gttgacgcgc tggcggaaga agcccctgta 1140
tatcataagc cgtcagcaga acccgcgtac taccgcgagt ttcaggaaac tgaagttccc 1200
gcgcctgaag taaaagacgc gacagagacg ctttttgccc tgctgcagca gccgacaatt 1260
gcgagcaaag agtgggtgta cgatcaatat gattacatgg tgcgcacgaa cacggtggtg 1320
gctccgggct ctgacgcggg agtgctcaga atccgcggca cgaaaaaggc gctggcaatg 1380
acgacggatt gcaacgcccg ctatttgtat ctcgatcctg aagaaggcgg aaaaatcgcc 1440
gttgccgaag cggcgcgcaa catcgtttgc tccggtgccg agccgcttgc ggtcacggat 1500
aatctgaatt tcggaaaccc ggaaaaacct gaaattttct ggcagatcga aaaagcggcc 1560
gacggcatca gcgaggcatg caatgttctc agcacacctg tcatcggcgg aaacgtatca 1620
ctttataatg aatcgaacgg aacggccatc tatccgacgc cggtcatcgg tatggtcggg 1680
ttaatcgaag atacggctca tattacgaca cagcatgtca aagcggcggg agacttgatt 1740
tacgtcatcg gtgaaacgaa gcctgagtat gcaggaagtg aacttcagaa aatgactgaa 1800
gggaaaatct atggcaaagc gcctgaaatt gatcttgacg ttgaaaaagc ccgccaaaca 1860
tcgcttctga acgccattaa acaaggtctg gtccaatctg cgcatgacgt gtcagaaggc 1920
ggattgggtg tggcgattgc agaaagcgtc atgacgacag acggactcgg cgcaaacatc 1980
acggcattta atgaagcggc tcttttgttc agtgagtctc aatcccgctt cgtcgtttcc 2040
gtaaaggaag aaaacaaggc ggcgtttgaa gcggctgcgg cagatgccgt tcatatcggt 2100
gaagtgacag gggacggaca gttgacgatc cgaagccaag aaggacaaca attggttcac 2160
gcgcaaacga aagaacttga gcgcgcgtgg aaaggagcta ttccatgctt gctgaaatca 2220
aaggcctga 2229
<210> 2
<211> 742
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Ser Leu Leu Leu Glu Pro Ser Lys Glu Gln Ile Lys Glu Glu Lys
1 5 10 15
Leu Tyr Gln Gln Met Gly Val Ser Asp Asp Glu Phe Ala Leu Ile Glu
20 25 30
Ser Ile Ile Gly Arg Leu Pro Asn Tyr Thr Glu Ile Gly Ile Phe Ser
35 40 45
Val Met Trp Ser Glu His Cys Ser Tyr Lys Asn Ser Lys Pro Ile Leu
50 55 60
Arg Lys Phe Pro Thr Ser Gly Glu Arg Val Leu Gln Gly Pro Gly Glu
65 70 75 80
Gly Ala Gly Ile Val Asp Ile Gly Asp Asn Gln Ala Val Val Phe Lys
85 90 95
Ile Glu Ser His Asn His Pro Ser Ala Leu Glu Pro Tyr Gln Gly Ala
100 105 110
Ala Thr Gly Val Gly Gly Ile Ile Arg Asp Val Phe Ser Met Gly Ala
115 120 125
Arg Pro Ile Ala Val Leu Asn Ser Leu Arg Phe Gly Glu Leu Thr Ser
130 135 140
Pro Arg Val Lys Tyr Leu Phe Glu Glu Val Val Ala Gly Ile Ala Gly
145 150 155 160
Tyr Gly Asn Cys Ile Gly Ile Pro Thr Val Gly Gly Glu Val Gln Phe
165 170 175
Asp Ala Ser Tyr Glu Gly Asn Pro Leu Val Asn Ala Met Cys Val Gly
180 185 190
Leu Ile Asp His Lys Asp Ile Lys Lys Gly Gln Ala Lys Gly Val Gly
195 200 205
Asn Thr Val Met Tyr Val Gly Ala Lys Thr Gly Arg Asp Gly Ile His
210 215 220
Gly Ala Thr Phe Ala Ser Glu Glu Met Ser Asp Ser Ser Glu Glu Lys
225 230 235 240
Arg Ser Ala Val Gln Val Gly Asp Pro Phe Met Glu Lys Leu Leu Leu
245 250 255
Glu Ala Cys Leu Glu Val Ile Gln Cys Asp Ala Leu Val Gly Ile Gln
260 265 270
Asp Met Gly Ala Ala Gly Leu Thr Ser Ser Ser Ala Glu Met Ala Ser
275 280 285
Lys Ala Gly Ser Gly Ile Glu Met Asn Leu Asp Leu Ile Pro Gln Arg
290 295 300
Glu Thr Gly Met Thr Ala Tyr Glu Met Met Leu Ser Glu Ser Gln Glu
305 310 315 320
Arg Met Leu Leu Val Ile Glu Arg Gly Arg Glu Gln Glu Ile Val Asp
325 330 335
Ile Phe Asn Lys Tyr Asp Leu Glu Ala Val Ser Val Gly His Val Thr
340 345 350
Asp Asp Lys Met Leu Arg Leu Arg His Asn Gly Glu Val Val Cys Glu
355 360 365
Leu Pro Val Asp Ala Leu Ala Glu Glu Ala Pro Val Tyr His Lys Pro
370 375 380
Ser Ala Glu Pro Ala Tyr Tyr Arg Glu Phe Gln Glu Thr Glu Val Pro
385 390 395 400
Ala Pro Glu Val Lys Asp Ala Thr Glu Thr Leu Phe Ala Leu Leu Gln
405 410 415
Gln Pro Thr Ile Ala Ser Lys Glu Trp Val Tyr Asp Gln Tyr Asp Tyr
420 425 430
Met Val Arg Thr Asn Thr Val Val Ala Pro Gly Ser Asp Ala Gly Val
435 440 445
Leu Arg Ile Arg Gly Thr Lys Lys Ala Leu Ala Met Thr Thr Asp Cys
450 455 460
Asn Ala Arg Tyr Leu Tyr Leu Asp Pro Glu Glu Gly Gly Lys Ile Ala
465 470 475 480
Val Ala Glu Ala Ala Arg Asn Ile Val Cys Ser Gly Ala Glu Pro Leu
485 490 495
Ala Val Thr Asp Asn Leu Asn Phe Gly Asn Pro Glu Lys Pro Glu Ile
500 505 510
Phe Trp Gln Ile Glu Lys Ala Ala Asp Gly Ile Ser Glu Ala Cys Asn
515 520 525
Val Leu Ser Thr Pro Val Ile Gly Gly Asn Val Ser Leu Tyr Asn Glu
530 535 540
Ser Asn Gly Thr Ala Ile Tyr Pro Thr Pro Val Ile Gly Met Val Gly
545 550 555 560
Leu Ile Glu Asp Thr Ala His Ile Thr Thr Gln His Val Lys Ala Ala
565 570 575
Gly Asp Leu Ile Tyr Val Ile Gly Glu Thr Lys Pro Glu Tyr Ala Gly
580 585 590
Ser Glu Leu Gln Lys Met Thr Glu Gly Lys Ile Tyr Gly Lys Ala Pro
595 600 605
Glu Ile Asp Leu Asp Val Glu Lys Ala Arg Gln Thr Ser Leu Leu Asn
610 615 620
Ala Ile Lys Gln Gly Leu Val Gln Ser Ala His Asp Val Ser Glu Gly
625 630 635 640
Gly Leu Gly Val Ala Ile Ala Glu Ser Val Met Thr Thr Asp Gly Leu
645 650 655
Gly Ala Asn Ile Thr Ala Phe Asn Glu Ala Ala Leu Leu Phe Ser Glu
660 665 670
Ser Gln Ser Arg Phe Val Val Ser Val Lys Glu Glu Asn Lys Ala Ala
675 680 685
Phe Glu Ala Ala Ala Ala Asp Ala Val His Ile Gly Glu Val Thr Gly
690 695 700
Asp Gly Gln Leu Thr Ile Arg Ser Gln Glu Gly Gln Gln Leu Val His
705 710 715 720
Ala Gln Thr Lys Glu Leu Glu Arg Ala Trp Lys Gly Ala Ile Pro Cys
725 730 735
Leu Leu Lys Ser Lys Ala
740
<210> 3
<211> 1431
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 3
atgcttgctg aaatcaaagg cctgaatgaa gaatgcggtg tgtttggcat ctgggggcat 60
gaagaggctc cgcagattac gtattacggc ctgcacagcc tgcagcacag agggcaggag 120
ggcgccggca tcgtggcgac cgacggccaa aaactgacgg ctcataaagg gcaggggctt 180
attaccgagg tttttcaaaa cggcgaactg agcaaagtga aaggcaaagg cgcgatcggt 240
cacgtccgct atgcgacggc cggcggcggc ggatatgaaa atgtccagcc gctcctgttc 300
cgttcgcaaa acaacggcag tctcgcgctc gcccataacg gcaacctggt caatgccaca 360
caattgaaac agcagcttga aaaccaaggg agcatctttc agacttcctc cgatacggaa 420
gtgctggctc atctgattaa acgcagcggc cacttttcac tgaaggatca gatcaaaaat 480
tcgctatcca tgctgaaagg cgcttacgcc tttttaatca tgacagaaac agaaatgatt 540
gtagcgcttg acccgaacgg actcagaccg ctttcactcg gcatgctcgg cgacgcttac 600
gtcgtcgcat cagaaacatg cgcatttgat gtggtcggcg ccacgtacct tcgtgacgta 660
gaaccgggcg aaatgcttat cataaacgat gaaggcttga aatcagagcg tttctccatg 720
aatatcaacc gttctatctg cagcatggag tatatctatt tttcccgtcc ggacagcaat 780
atcgacggca ttaacgtgca cagcgcccgg aagagcctcg ggaaaatgct tgcccaagag 840
tccgctgttg aagcggatgt cgtcacaggc gtgcctgatt ccagtatttc cgcggccatc 900
ggctatgccg aggcaacggg cattccgtac gaactcggtc tcattaaaaa ccgttacgtc 960
ggcagaacgt ttatccagcc gtctcaagct cttcgtgagc aaggagtaag aatgaagctg 1020
tccgccgtcc gcggtgttgt tgaaggaaaa cgggtcgtca tggttgatga ttccatcgtg 1080
cgcgggacga caagccgccg gatcgtcaca atgctccgag aagcgggagc gacagaggtg 1140
catgtaaaga tcagttcgcc tccgatcgcc catccttgct tctacggcat cgacacatca 1200
acccatgagg agctgatcgc ttcctcgcat tcagtggaag aaatccgcca gattatcggc 1260
gccgacacgc tttctttctt aagtgtagac ggattgttaa aaggagtcgg ccgaaaattt 1320
gaagacacca attgcggaca atgcctcgct tgttttacgg gcaaatatcc gacggaaatt 1380
tatcaggata cagtgcttcc tcacgtaaaa gaagcagtgc tgacaaaata a 1431
<210> 4
<211> 476
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Met Leu Ala Glu Ile Lys Gly Leu Asn Glu Glu Cys Gly Val Phe Gly
1 5 10 15
Ile Trp Gly His Glu Glu Ala Pro Gln Ile Thr Tyr Tyr Gly Leu His
20 25 30
Ser Leu Gln His Arg Gly Gln Glu Gly Ala Gly Ile Val Ala Thr Asp
35 40 45
Gly Gln Lys Leu Thr Ala His Lys Gly Gln Gly Leu Ile Thr Glu Val
50 55 60
Phe Gln Asn Gly Glu Leu Ser Lys Val Lys Gly Lys Gly Ala Ile Gly
65 70 75 80
His Val Arg Tyr Ala Thr Ala Gly Gly Gly Gly Tyr Glu Asn Val Gln
85 90 95
Pro Leu Leu Phe Arg Ser Gln Asn Asn Gly Ser Leu Ala Leu Ala His
100 105 110
Asn Gly Asn Leu Val Asn Ala Thr Gln Leu Lys Gln Gln Leu Glu Asn
115 120 125
Gln Gly Ser Ile Phe Gln Thr Ser Ser Asp Thr Glu Val Leu Ala His
130 135 140
Leu Ile Lys Arg Ser Gly His Phe Ser Leu Lys Asp Gln Ile Lys Asn
145 150 155 160
Ser Leu Ser Met Leu Lys Gly Ala Tyr Ala Phe Leu Ile Met Thr Glu
165 170 175
Thr Glu Met Ile Val Ala Leu Asp Pro Asn Gly Leu Arg Pro Leu Ser
180 185 190
Leu Gly Met Leu Gly Asp Ala Tyr Val Val Ala Ser Glu Thr Cys Ala
195 200 205
Phe Asp Val Val Gly Ala Thr Tyr Leu Arg Asp Val Glu Pro Gly Glu
210 215 220
Met Leu Ile Ile Asn Asp Glu Gly Leu Lys Ser Glu Arg Phe Ser Met
225 230 235 240
Asn Ile Asn Arg Ser Ile Cys Ser Met Glu Tyr Ile Tyr Phe Ser Arg
245 250 255
Pro Asp Ser Asn Ile Asp Gly Ile Asn Val His Ser Ala Arg Lys Ser
260 265 270
Leu Gly Lys Met Leu Ala Gln Glu Ser Ala Val Glu Ala Asp Val Val
275 280 285
Thr Gly Val Pro Asp Ser Ser Ile Ser Ala Ala Ile Gly Tyr Ala Glu
290 295 300
Ala Thr Gly Ile Pro Tyr Glu Leu Gly Leu Ile Lys Asn Arg Tyr Val
305 310 315 320
Gly Arg Thr Phe Ile Gln Pro Ser Gln Ala Leu Arg Glu Gln Gly Val
325 330 335
Arg Met Lys Leu Ser Ala Val Arg Gly Val Val Glu Gly Lys Arg Val
340 345 350
Val Met Val Asp Asp Ser Ile Val Arg Gly Thr Thr Ser Arg Arg Ile
355 360 365
Val Thr Met Leu Arg Glu Ala Gly Ala Thr Glu Val His Val Lys Ile
370 375 380
Ser Ser Pro Pro Ile Ala His Pro Cys Phe Tyr Gly Ile Asp Thr Ser
385 390 395 400
Thr His Glu Glu Leu Ile Ala Ser Ser His Ser Val Glu Glu Ile Arg
405 410 415
Gln Ile Ile Gly Ala Asp Thr Leu Ser Phe Leu Ser Val Asp Gly Leu
420 425 430
Leu Lys Gly Val Gly Arg Lys Phe Glu Asp Thr Asn Cys Gly Gln Cys
435 440 445
Leu Ala Cys Phe Thr Gly Lys Tyr Pro Thr Glu Ile Tyr Gln Asp Thr
450 455 460
Val Leu Pro His Val Lys Glu Ala Val Leu Thr Lys
465 470 475
<210> 5
<211> 2229
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 5
atgtcactac tgcttgaacc aagtaaagaa caaataaaag aagagaaact gtatcagcaa 60
atgggtgtca gtgatgatga gtttgcattg atagaatcca ttcttggaag attgccgaac 120
tacacagaaa tcggaatttt ttctgtcatg tggtctgagc attgcagcta taaaaactca 180
aagccgattc tgcgtaaatt cccgacaagc ggcgagcgtg tgctgcaggg gccgggggaa 240
ggcgccggaa tcgttgatat cggtgataac caagcggttg tgttcaaaat tgaatcacat 300
aaccacccat cagctctcga gccttaccaa ggcgctgcga ctggcgtagg cggaattatc 360
cgtgatgtat tctcaatggg tgcacgccca atcgctgtat tgaactctct tcgatttggt 420
gaactgactt caccccgcgt gaagtacttg tttgaagaag tagtagcggg tatcgccgga 480
tacggcaact gtatcggcat cccgacagtc ggcggagaag tgcagtttga cagcagctat 540
gaaggaaatc cgctcgtcaa cgcaatgtgc gtcggtttaa tcaaccatga agacatcaaa 600
aaaggccagg caaagggtgt cggcaacaca gtaatgtacg taggagcgaa aacagggcgt 660
gacggcatcc acggcgctac gtttgcttct gaagaaatgt cagactcgtc tgaagaaaag 720
cgttctgctg tccaagtcgg cgatccgttt atggagaagc ttttgcttga agcatgtctg 780
gaagtcatcc aatgcgacgc cttagtcggc attcaggata tgggagctgc cggtttaaca 840
agctcaagtg cagaaatggc aagtaaagcc ggttctggca ttgaaatgaa tcttgacctg 900
attcctcagc gcgaaacagg catgaccgcg tatgaaatga tgctttctga atcacaagaa 960
cggatgcttt tggttattga gcgcggacgt gagcaggaaa tcatcgatat ttttgacaag 1020
tatgatcttg aagcggtttc tgtcggacat gtgacagatg ataaaatgct tcgcctgaca 1080
cataaaggag aggttgtgtg cgagctgcct gttgatgcct tggcagaaga agcaccggtt 1140
taccataagc cttctcaaga gcctgcttac tatcgcgagt ttttggaaac agacgttccg 1200
gctccgcaaa ttgaagatgc gaatgaaatg ctgaaggccc ttcttcagca gccgacgatt 1260
gcgagtaaag agtgggttta tgatcagtat gactacatgg tgcgcacgaa tacagttgtc 1320
gctcctgggt ctgatgctgg tgttctcaga atccgcggaa cgaaaaaggc gctggcgatg 1380
acgacagact gtaacgcgcg ttatctctat cttgatcctg aagtcggagg gaaaattgct 1440
gtcgctgaag cagcgcgcaa catcatttgc tcaggcgcag aaccgcttgc ggtgacagat 1500
aaccttaact tcggaaaccc tgagaagccg gaaatcttct ggcagatcga aaaagcggca 1560
gacggcataa gcgaagcgtg caatgttctc agcactccgg ttatcggcgg taacgtatcg 1620
ctttataacg aatcaaacgg cacggcgatc tatccgacac cagttatcgg catggtcggc 1680
ctaattgaag atacagcgca cattacaaca cagcatttca aacaagcagg agatctcgta 1740
tacgtgatcg gcgaaacaaa accagagttt gccggaagcg agctgcaaaa aatgacagaa 1800
ggccgtattt acggcaaagc gccgcaaatc gatcttgatg tagagctgtc tcgtcaaaaa 1860
gcactgcttg acgcgattaa aaaaggcttc gttcaatctg cgcatgatgt gtctgaaggc 1920
ggcttaggcg tagcgattgc ggaaagtgtc atgacgacgg aaaaccttgg cgctaatgtg 1980
actgtagaag gggaagcggc gttattattc tctgaatctc aatctcgctt cgtcgtttca 2040
gtgaaaaaag aacatcaagc tgcgtttgaa gcaactgtca aagatgcagt tcatattggt 2100
gaggtaacag ctgacggaat tctggcgatt caaaaccaag acggacaaca aatgattcat 2160
gcgcaaacga aagagcttga acgcgtatgg aaaggagcta tcccatgctt gctgaaatca 2220
aaggcttaa 2229
<210> 6
<211> 742
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Met Ser Leu Leu Leu Glu Pro Ser Lys Glu Gln Ile Lys Glu Glu Lys
1 5 10 15
Leu Tyr Gln Gln Met Gly Val Ser Asp Asp Glu Phe Ala Leu Ile Glu
20 25 30
Ser Ile Leu Gly Arg Leu Pro Asn Tyr Thr Glu Ile Gly Ile Phe Ser
35 40 45
Val Met Trp Ser Glu His Cys Ser Tyr Lys Asn Ser Lys Pro Ile Leu
50 55 60
Arg Lys Phe Pro Thr Ser Gly Glu Arg Val Leu Gln Gly Pro Gly Glu
65 70 75 80
Gly Ala Gly Ile Val Asp Ile Gly Asp Asn Gln Ala Val Val Phe Lys
85 90 95
Ile Glu Ser His Asn His Pro Ser Ala Leu Glu Pro Tyr Gln Gly Ala
100 105 110
Ala Thr Gly Val Gly Gly Ile Ile Arg Asp Val Phe Ser Met Gly Ala
115 120 125
Arg Pro Ile Ala Val Leu Asn Ser Leu Arg Phe Gly Glu Leu Thr Ser
130 135 140
Pro Arg Val Lys Tyr Leu Phe Glu Glu Val Val Ala Gly Ile Ala Gly
145 150 155 160
Tyr Gly Asn Cys Ile Gly Ile Pro Thr Val Gly Gly Glu Val Gln Phe
165 170 175
Asp Ser Ser Tyr Glu Gly Asn Pro Leu Val Asn Ala Met Cys Val Gly
180 185 190
Leu Ile Asn His Glu Asp Ile Lys Lys Gly Gln Ala Lys Gly Val Gly
195 200 205
Asn Thr Val Met Tyr Val Gly Ala Lys Thr Gly Arg Asp Gly Ile His
210 215 220
Gly Ala Thr Phe Ala Ser Glu Glu Met Ser Asp Ser Ser Glu Glu Lys
225 230 235 240
Arg Ser Ala Val Gln Val Gly Asp Pro Phe Met Glu Lys Leu Leu Leu
245 250 255
Glu Ala Cys Leu Glu Val Ile Gln Cys Asp Ala Leu Val Gly Ile Gln
260 265 270
Asp Met Gly Ala Ala Gly Leu Thr Ser Ser Ser Ala Glu Met Ala Ser
275 280 285
Lys Ala Gly Ser Gly Ile Glu Met Asn Leu Asp Leu Ile Pro Gln Arg
290 295 300
Glu Thr Gly Met Thr Ala Tyr Glu Met Met Leu Ser Glu Ser Gln Glu
305 310 315 320
Arg Met Leu Leu Val Ile Glu Arg Gly Arg Glu Gln Glu Ile Ile Asp
325 330 335
Ile Phe Asp Lys Tyr Asp Leu Glu Ala Val Ser Val Gly His Val Thr
340 345 350
Asp Asp Lys Met Leu Arg Leu Thr His Lys Gly Glu Val Val Cys Glu
355 360 365
Leu Pro Val Asp Ala Leu Ala Glu Glu Ala Pro Val Tyr His Lys Pro
370 375 380
Ser Gln Glu Pro Ala Tyr Tyr Arg Glu Phe Leu Glu Thr Asp Val Pro
385 390 395 400
Ala Pro Gln Ile Glu Asp Ala Asn Glu Met Leu Lys Ala Leu Leu Gln
405 410 415
Gln Pro Thr Ile Ala Ser Lys Glu Trp Val Tyr Asp Gln Tyr Asp Tyr
420 425 430
Met Val Arg Thr Asn Thr Val Val Ala Pro Gly Ser Asp Ala Gly Val
435 440 445
Leu Arg Ile Arg Gly Thr Lys Lys Ala Leu Ala Met Thr Thr Asp Cys
450 455 460
Asn Ala Arg Tyr Leu Tyr Leu Asp Pro Glu Val Gly Gly Lys Ile Ala
465 470 475 480
Val Ala Glu Ala Ala Arg Asn Ile Ile Cys Ser Gly Ala Glu Pro Leu
485 490 495
Ala Val Thr Asp Asn Leu Asn Phe Gly Asn Pro Glu Lys Pro Glu Ile
500 505 510
Phe Trp Gln Ile Glu Lys Ala Ala Asp Gly Ile Ser Glu Ala Cys Asn
515 520 525
Val Leu Ser Thr Pro Val Ile Gly Gly Asn Val Ser Leu Tyr Asn Glu
530 535 540
Ser Asn Gly Thr Ala Ile Tyr Pro Thr Pro Val Ile Gly Met Val Gly
545 550 555 560
Leu Ile Glu Asp Thr Ala His Ile Thr Thr Gln His Phe Lys Gln Ala
565 570 575
Gly Asp Leu Val Tyr Val Ile Gly Glu Thr Lys Pro Glu Phe Ala Gly
580 585 590
Ser Glu Leu Gln Lys Met Thr Glu Gly Arg Ile Tyr Gly Lys Ala Pro
595 600 605
Gln Ile Asp Leu Asp Val Glu Leu Ser Arg Gln Lys Ala Leu Leu Asp
610 615 620
Ala Ile Lys Lys Gly Phe Val Gln Ser Ala His Asp Val Ser Glu Gly
625 630 635 640
Gly Leu Gly Val Ala Ile Ala Glu Ser Val Met Thr Thr Glu Asn Leu
645 650 655
Gly Ala Asn Val Thr Val Glu Gly Glu Ala Ala Leu Leu Phe Ser Glu
660 665 670
Ser Gln Ser Arg Phe Val Val Ser Val Lys Lys Glu His Gln Ala Ala
675 680 685
Phe Glu Ala Thr Val Lys Asp Ala Val His Ile Gly Glu Val Thr Ala
690 695 700
Asp Gly Ile Leu Ala Ile Gln Asn Gln Asp Gly Gln Gln Met Ile His
705 710 715 720
Ala Gln Thr Lys Glu Leu Glu Arg Val Trp Lys Gly Ala Ile Pro Cys
725 730 735
Leu Leu Lys Ser Lys Ala
740
<210> 7
<211> 1431
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 7
atgcttgctg aaatcaaagg cttaaatgaa gaatgcggcg tttttgggat ttggggacat 60
gaagaagccc cgcaaatcac gtattacggt ctccacagcc ttcagcaccg aggacaggag 120
ggtgctggca tcgtagcgac tgacggtgaa aagctgacgg ctcacaaagg ccaaggtctg 180
atcactgaag tatttcaaaa cggcgaactc agcaaagtaa agggaaaagg cgctatcggg 240
cacgttcggt acgcaacggc tggaggcggc ggatacgaaa atgttcagcc gctcctcttc 300
cgttcccaaa acaacggcag cctggcgctt gctcataacg gaaatcttgt caacgccact 360
cagctgaagc agcagctcga aaatcaaggg agcatctttc aaacctcttc ggatacagag 420
gttttggctc acctgatcaa aagaagcgga cacttcacgc tgaaggatca aattaaaaac 480
tcgctttcta tgctgaaagg cgcctacgcg ttcctgatca tgaccgaaac agaaatgatt 540
gtcgcacttg atccaaacgg gctgagaccg ctatccatcg gcatgatggg cgacgcttat 600
gtggtcgcat cagaaacatg cgcatttgac gtcgtcggcg caacgtacct tcgcgaggta 660
gagccgggag aaatgctgat cattaatgat gaaggcatga aatcagagcg tttttccatg 720
aatatcaatc gttccatttg cagcatggag tacatttatt tctccagacc agacagcaat 780
attgacggta ttaatgtgca cagtgcccgt aaaaaccttg ggaaaatgct ggctcaggaa 840
tccgcagttg aagctgacgt cgtaaccggg gttccggatt ccagtatttc agcggcgatc 900
ggctatgcag aggcaacagg cattccgtat gagcttggct taatcaaaaa ccgttatgtt 960
ggcagaacgt ttattcagcc gtcccaggct ctgcgtgagc aaggcgtcag aatgaagctg 1020
tctgcggtgc gcggggttgt agaaggcaaa cgcgtcgtga tggtggatga ctctatcgtg 1080
cgaggaacaa ctagccgccg gattgtcacg atgctaagag aagcgggtgc gacagaggtg 1140
catgtgaaaa tcagttcacc gccgatcgct catccgtgct tttacggcat tgacacttcc 1200
acacatgaag aactgatcgc gtcttcgcat tctgttgaag aaatccgtca ggaaatcgga 1260
gccgataccc tctcattttt gagtgtggaa gggctgctga aaggcatcgg cagaaaatac 1320
gatgactcga attgcggaca gtgtctcgct tgctttacag gaaaatatcc gactgaaatt 1380
taccaggata cagtgcttcc tcacgtaaaa gaagcagtat taaccaaata a 1431
<210> 8
<211> 476
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Met Leu Ala Glu Ile Lys Gly Leu Asn Glu Glu Cys Gly Val Phe Gly
1 5 10 15
Ile Trp Gly His Glu Glu Ala Pro Gln Ile Thr Tyr Tyr Gly Leu His
20 25 30
Ser Leu Gln His Arg Gly Gln Glu Gly Ala Gly Ile Val Ala Thr Asp
35 40 45
Gly Glu Lys Leu Thr Ala His Lys Gly Gln Gly Leu Ile Thr Glu Val
50 55 60
Phe Gln Asn Gly Glu Leu Ser Lys Val Lys Gly Lys Gly Ala Ile Gly
65 70 75 80
His Val Arg Tyr Ala Thr Ala Gly Gly Gly Gly Tyr Glu Asn Val Gln
85 90 95
Pro Leu Leu Phe Arg Ser Gln Asn Asn Gly Ser Leu Ala Leu Ala His
100 105 110
Asn Gly Asn Leu Val Asn Ala Thr Gln Leu Lys Gln Gln Leu Glu Asn
115 120 125
Gln Gly Ser Ile Phe Gln Thr Ser Ser Asp Thr Glu Val Leu Ala His
130 135 140
Leu Ile Lys Arg Ser Gly His Phe Thr Leu Lys Asp Gln Ile Lys Asn
145 150 155 160
Ser Leu Ser Met Leu Lys Gly Ala Tyr Ala Phe Leu Ile Met Thr Glu
165 170 175
Thr Glu Met Ile Val Ala Leu Asp Pro Asn Gly Leu Arg Pro Leu Ser
180 185 190
Ile Gly Met Met Gly Asp Ala Tyr Val Val Ala Ser Glu Thr Cys Ala
195 200 205
Phe Asp Val Val Gly Ala Thr Tyr Leu Arg Glu Val Glu Pro Gly Glu
210 215 220
Met Leu Ile Ile Asn Asp Glu Gly Met Lys Ser Glu Arg Phe Ser Met
225 230 235 240
Asn Ile Asn Arg Ser Ile Cys Ser Met Glu Tyr Ile Tyr Phe Ser Arg
245 250 255
Pro Asp Ser Asn Ile Asp Gly Ile Asn Val His Ser Ala Arg Lys Asn
260 265 270
Leu Gly Lys Met Leu Ala Gln Glu Ser Ala Val Glu Ala Asp Val Val
275 280 285
Thr Gly Val Pro Asp Ser Ser Ile Ser Ala Ala Ile Gly Tyr Ala Glu
290 295 300
Ala Thr Gly Ile Pro Tyr Glu Leu Gly Leu Ile Lys Asn Arg Tyr Val
305 310 315 320
Gly Arg Thr Phe Ile Gln Pro Ser Gln Ala Leu Arg Glu Gln Gly Val
325 330 335
Arg Met Lys Leu Ser Ala Val Arg Gly Val Val Glu Gly Lys Arg Val
340 345 350
Val Met Val Asp Asp Ser Ile Val Arg Gly Thr Thr Ser Arg Arg Ile
355 360 365
Val Thr Met Leu Arg Glu Ala Gly Ala Thr Glu Val His Val Lys Ile
370 375 380
Ser Ser Pro Pro Ile Ala His Pro Cys Phe Tyr Gly Ile Asp Thr Ser
385 390 395 400
Thr His Glu Glu Leu Ile Ala Ser Ser His Ser Val Glu Glu Ile Arg
405 410 415
Gln Glu Ile Gly Ala Asp Thr Leu Ser Phe Leu Ser Val Glu Gly Leu
420 425 430
Leu Lys Gly Ile Gly Arg Lys Tyr Asp Asp Ser Asn Cys Gly Gln Cys
435 440 445
Leu Ala Cys Phe Thr Gly Lys Tyr Pro Thr Glu Ile Tyr Gln Asp Thr
450 455 460
Val Leu Pro His Val Lys Glu Ala Val Leu Thr Lys
465 470 475
<210> 9
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 9
caaaataagg atcctctaga gtcgacgaag tcatccagtg cgacgc 46
<210> 10
<211> 40
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 10
tctgagcact cccgcgtcaa agcccggagc caccaccgtg 40
<210> 11
<211> 40
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 11
cacggtggtg gctccgggct ttgacgcggg agtgctcaga 40
<210> 12
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 12
ccagtgccaa gcttgcatgc ctgcaggcgt cgcactggat gacttc 46
<210> 13
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 13
caaaataagg atcctctaga gtcgaccact tttcactgaa ggatca 46
<210> 14
<211> 40
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 14
aacggttttt aatgagaccg ggttcgtacg gaatgcccgt 40
<210> 15
<211> 40
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 15
acgggcattc cgtacgaacc cggtctcatt aaaaaccgtt 40
<210> 16
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 16
ccagtgccaa gcttgcatgc ctgcaggcac tgcttctttt acgtga 46
<210> 17
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 17
caaaataagg atcctctaga gtcgaccggt ttaacaagct caagtg 46
<210> 18
<211> 40
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 18
tctgagaaca ccagcatcaa acccaggagc gacaactgta 40
<210> 19
<211> 40
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 19
tacagttgtc gctcctgggt ttgatgctgg tgttctcaga 40
<210> 20
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 20
ccagtgccaa gcttgcatgc ctgcaggctt tgccgtaaat acggcc 46
<210> 21
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 21
caaaataagg atcctctaga gtcgacaaga agcggacact tcacgc 46
<210> 22
<211> 40
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 22
cggtttttga ttaagccagg ctcatacgga atgcctgttg 40
<210> 23
<211> 40
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 23
caacaggcat tccgtatgag cctggcttaa tcaaaaaccg 40
<210> 24
<211> 46
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 24
ccagtgccaa gcttgcatgc ctgcagatac tgcttctttt acgtga 46
<210> 25
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 25
Glu Lys Asx Cys Ser Gln Leu Phe Met Asn His Asp
1 5 10

Claims (10)

1.可提高芽孢杆菌核苷产量的突变体,其特征在于,其包括:
1)磷酸核糖基甲酰基甘氨酰胺合酶突变体,其在野生型序列如SEQ ID NO .2或SEQ IDNO .6所示的磷酸核糖基甲酰基甘氨酰胺合酶的基础上,第444位丝氨酸突变为苯丙氨酸;和/或,
2)酰胺基磷酸核糖基转移酶突变体,其在野生型序列如SEQ ID NO .4或SEQ ID NO .8所示的酰胺基磷酸核糖基转移酶的基础上,第312位亮氨酸突变为脯氨酸;
所述芽孢杆菌为解淀粉芽孢杆菌或枯草芽孢杆菌。
2.根据权利要求1所述的突变体,其特征在于,编码磷酸核糖基甲酰基甘氨酰胺合酶野生型的基因的核苷酸序列如SEQ ID NO .1或SEQ ID NO .5所示。
3.根据权利要求1或2所述的突变体,其特征在于,编码酰胺基磷酸核糖基转移酶野生型的基因的核苷酸序列如SEQ ID NO .3或SEQ ID NO .7所示。
4.编码权利要求1-3中任一项所述的突变体的核酸。
5.权利要求1-3中任一项所述的突变体或权利要求4所述的核酸在以下任一方面的应用:
(1)构建生产核苷的芽孢杆菌;
(2)筛选生产核苷的芽孢杆菌;
所述芽孢杆菌为解淀粉芽孢杆菌或枯草芽孢杆菌。
6.一种芽孢杆菌,其特征在于,其表达权利要求1-3中任一项所述的突变体;和/或,其含有权利要求4所述的核酸;
所述芽孢杆菌为解淀粉芽孢杆菌或枯草芽孢杆菌。
7.权利要求6所述的芽孢杆菌在生产核苷中的应用;
所述核苷为肌苷、腺苷中的一种或两种。
8.一种生产核苷的方法,其特征在于,包括:培养权利要求6所述的芽孢杆菌,以产生、积累和收集核苷。
9.根据权利要求8所述的方法,其特征在于,包括:将所述芽孢杆菌接种于种子培养基进行扩繁,然后将扩繁后的培养物转入发酵培养基发酵;
所述种子培养基的配方如下:
葡萄糖20 g/L,酵母粉5 g/L,玉米浆干粉5 g/L,磷酸二氢钾3 g/L,硫酸镁0.5 g/L,硫酸亚铁0.02 g/L,硫酸锰0.01 g/L,pH 7.0~7.2;
所述发酵培养基的配方如下:
葡萄糖60 g/L,酵母粉3.5 g/L,磷酸二氢钾3 g/L,硫酸铵25 g/L,硫酸锰0.01 g/L,硫酸镁5 g/L,味精10 g/L,玉米浆干粉15 g/L,碳酸钙25 g/L,pH 7.0~7.2。
10.根据权利要求9所述的方法,其特征在于,所述发酵的温度为35-36℃。
CN202110567676.9A 2021-05-24 2021-05-24 可提高芽孢杆菌核苷产量的突变体及其应用 Active CN113278596B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110567676.9A CN113278596B (zh) 2021-05-24 2021-05-24 可提高芽孢杆菌核苷产量的突变体及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110567676.9A CN113278596B (zh) 2021-05-24 2021-05-24 可提高芽孢杆菌核苷产量的突变体及其应用

Publications (2)

Publication Number Publication Date
CN113278596A CN113278596A (zh) 2021-08-20
CN113278596B true CN113278596B (zh) 2022-07-29

Family

ID=77281333

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110567676.9A Active CN113278596B (zh) 2021-05-24 2021-05-24 可提高芽孢杆菌核苷产量的突变体及其应用

Country Status (1)

Country Link
CN (1) CN113278596B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114317386B (zh) * 2021-12-06 2023-12-08 天津科技大学 一种生产肌苷的基因工程菌株及其构建方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111718915A (zh) * 2020-06-16 2020-09-29 仙居两山生物科技有限公司 一种烟酰胺磷酸核糖转移酶突变体、包含该突变体的重组表达载体和重组菌及应用
CN112538453A (zh) * 2020-12-15 2021-03-23 通辽梅花生物科技有限公司 一种产核黄素的枯草芽孢杆菌及其构建方法与应用
CN112574934A (zh) * 2020-10-12 2021-03-30 廊坊梅花生物技术开发有限公司 高产鸟苷的工程菌及其构建方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840678D1 (de) * 1997-07-18 2009-04-30 Ajinomoto Kk Verfahren zur produktion von purinnukleosiden durch fermentation
CN112126666B (zh) * 2020-09-22 2022-04-08 廊坊梅花生物技术开发有限公司 核苷高产菌及其构建方法与应用
CN112143751B (zh) * 2020-09-22 2022-05-06 廊坊梅花生物技术开发有限公司 高产核苷的枯草芽孢杆菌工程菌及其构建方法与应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111718915A (zh) * 2020-06-16 2020-09-29 仙居两山生物科技有限公司 一种烟酰胺磷酸核糖转移酶突变体、包含该突变体的重组表达载体和重组菌及应用
CN112574934A (zh) * 2020-10-12 2021-03-30 廊坊梅花生物技术开发有限公司 高产鸟苷的工程菌及其构建方法与应用
CN112538453A (zh) * 2020-12-15 2021-03-23 通辽梅花生物科技有限公司 一种产核黄素的枯草芽孢杆菌及其构建方法与应用

Also Published As

Publication number Publication date
CN113278596A (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
CN101432418B (zh) 能够产生嘌呤物质的细菌和用于产生嘌呤物质的方法
CN101432417B (zh) 能够产生嘌呤物质的细菌和用于产生嘌呤物质的方法
EP1700910A2 (en) Purine-derived substance-producing Bacillus and a method for producing purine-derived substance therewith
CN106754602A (zh) 一种生产胞苷的重组微生物及生产胞苷的方法
CN112143751B (zh) 高产核苷的枯草芽孢杆菌工程菌及其构建方法与应用
KR20010021986A (ko) 발효에 의한 퓨린 뉴클레오사이드의 제조 방법
CN110257315B (zh) 一种枯草芽孢杆菌及其构建方法与应用
US8187840B2 (en) Microorganism producing inosine and method of producing inosine using the same
CN112574934B (zh) 高产鸟苷的工程菌及其构建方法与应用
WO2010038903A1 (en) A method for producing purine ribonucleosides and ribonucleotides
CN113755414B (zh) 一种生产尿苷的重组微生物及生产尿苷的方法
CN113265382A (zh) 多聚磷酸激酶突变体
KR101210704B1 (ko) 5&#39;-크산틸산 및 5&#39;-구아닐산 생산능이 향상된 미생물 및 이를 이용한 5&#39;-크산틸산 또는 5&#39;-구아닐산의 생산방법
CN116463273A (zh) 增强5’-胞苷酸积累的方法及应用
CN113278596B (zh) 可提高芽孢杆菌核苷产量的突变体及其应用
CN112126666B (zh) 核苷高产菌及其构建方法与应用
EP0504279B1 (en) Fermentation process for the production of pyrimidine deoxyribonucleosides
KR100957689B1 (ko) 5&#39;-구아노신 모노포스페이트 생산능이 향상된코리네박테리움 속 미생물 및 이를 이용한 5&#39;-구아노신모노포스페이트의 생산방법
CN113755416A (zh) 具有新合成路径生产β-胸苷的重组微生物及生产β-胸苷的方法
CN102317433A (zh) 具有提高的5’-黄苷一磷酸生产力的棒状菌菌株和用其生产5’-黄苷一磷酸的方法
CN113151238B (zh) 磷酸戊糖变位酶突变体及其在构建高产核苷的枯草芽孢杆菌中的应用
JP2008543272A (ja) Xmpをgmpに転換させることができながら、gmpの分解に関連される遺伝子が不活性化されているエシェリキア菌株及びそれを用いる方法
CN116904430A (zh) 可提高菌株核苷产量的蛋白突变体及其应用
CN115678876A (zh) 可提高菌株核苷产量的蛋白突变体及其应用
CN115678909A (zh) 弱化鸟苷酸激酶在提高菌株生产核苷或其衍生物的能力中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant